Helicobacter pylori: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control
Diseases · 03.12.2024 · 12 (12) · 311
DOI: 10.3390/diseases12120311 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diseases, online erschienen am 03.12.2024. Verfasst von Ayman Elbehiry und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 273 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Nosokomiale Infektionen
Abstract (Originalsprache)
Helicobacter pylori (H. pylori) is a Gram-negative, spiral-shaped bacterium that colonizes the gastric epithelium and is associated with a range of gastrointestinal disorders, exhibiting a global prevalence of approximately 50%. Despite the availability of treatment options, H. pylori frequently reemerges and demonstrates increasing antibiotic resistance, which diminishes the efficacy of conventional therapies. Consequently, it is imperative to explore non-antibiotic treatment alternatives to mitigate the inappropriate use of antibiotics. This review examines H. pylori infection, encompassing transmission pathways, treatment modalities, antibiotic resistance, and eradication strategies. Additionally, it discusses alternative therapeutic approaches such as probiotics, anti-biofilm agents, phytotherapy, phototherapy, phage therapy, lactoferrin therapy, and vaccine development. These strategies aim to reduce antimicrobial resistance and enhance treatment outcomes for H. pylori infections. While alternative therapies can maintain low bacterial levels, they do not achieve complete eradication of H. pylori. These therapies are designed to bolster the immune response, minimize side effects, and provide gastroprotective benefits, rendering them suitable for adjunctive use alongside conventional treatments. Probiotics may serve as adjunctive therapy for H. pylori; however, their effectiveness as a monotherapy is limited. Photodynamic and phage therapies exhibit potential in targeting H. pylori infections, including those caused by drug-resistant strains, without the use of antibiotics. The development of a reliable vaccine is also critical for the eradication of H. pylori. This review identifies candidate antigens such as VacA, CagA, and HspA, along with various vaccine formulations, including vector-based and subunit vaccines. Some vaccines have demonstrated efficacy in clinical trials, while others have shown robust immune protection in preclinical studies. Nevertheless, each of the aforementioned alternative therapies requires thorough preclinical and clinical evaluation to ascertain their efficacy, side effects, cost-effectiveness, and patient compliance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia.
- Medical Emergency Services Department, Faculty of Health Sciences, Umm Al-Qura University, Al-Qunfudah P.O. Box 1109, Saudi Arabia.
- Department of Preventive Medicine, King Fahad Armed Hospital, Jeddah 23311, Saudi Arabia.
- Pathology and Laboratory Medicine Department, Armed Forces Hospital-Jubail, Jubail 31951, Saudi Arabia.
- Medical Radiology Department, Armed Forces Hospital-Jubail, Jubail 31951, Saudi Arabia.
- Biomedical Engineer, Armed Forces Medical Services, Riyadh 12426, Saudi Arabia.
ORCID-Profile: Ayman Elbehiry, Adil Abalkhail, Nuha Anajirih, Mohammed Rawway, Moustafa H Abdelsalam, Mohamed E A Mostafa
Zitieren
APA
Elbehiry, A., Abalkhail, A., Anajirih, N., Alkhamisi, F., Aldamegh, M., Alramzi, A., AlShaqi, R., Alotaibi, N., Aljuaid, A., Alzahrani, H., Alzaben, F., Rawway, M., Ibrahem, M., Abdelsalam, M. H., Rizk, N. I., Mostafa, M. E. A., Alfaqir, M. R., Edrees, H. M., & Alqahtani, M. (2024). Helicobacter pylori: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control. Diseases, 12(12), 311. https://doi.org/10.3390/diseases12120311
Vancouver
Elbehiry A, Abalkhail A, Anajirih N, Alkhamisi F, Aldamegh M, Alramzi A, et al. Helicobacter pylori: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control. Diseases. 2024;12(12):311. doi:10.3390/diseases12120311
BibTeX
@article{Elbehiry2024,
author = {Elbehiry, Ayman and Abalkhail, Adil and Anajirih, Nuha and Alkhamisi, Fahad and Aldamegh, Mohammed and Alramzi, Abdullah and AlShaqi, Riyad and Alotaibi, Naif and Aljuaid, Abdullah and Alzahrani, Hilal and Alzaben, Feras and Rawway, Mohammed and Ibrahem, Mai and Abdelsalam, Moustafa H and Rizk, Nermin I and Mostafa, Mohamed E A and Alfaqir, Moneef Rohail and Edrees, Husam M and Alqahtani, Mubarak},
title = {Helicobacter pylori: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control},
journal = {Diseases},
year = {2024},
volume = {12},
number = {12},
pages = {311},
doi = {10.3390/diseases12120311}
}
EUVIMED